利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.022 秒)

    DRUG DELIVERY FROM HYDROGELS
    1.
    发明公开
    DRUG DELIVERY FROM HYDROGELS 审中-公开

    公开(公告)号：EP4279064A3

    公开(公告)日：2024-02-28

    申请号：EP23200018.2

    申请日：2016-05-12

    申请人： Incept, LLC

    发明人： JARRETT, Peter ,  EL-HAYEK, Rami ,  JARRETT, Timothy, S. ,  BLIZZARD, Charles D. ,  SAWHNEY, Amarpreet, S.

    IPC分类号： A61F2/14 ,  A61F9/00 ,  A61P27/02 ,  A61K9/00

    摘要： Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed in the hydrogel, the agent having a low solubility in water. The agent may be essentially insoluble in water. The hydrogel may be made so that 50% to 100% w/w of the agent is released when the hydrogel is from 100% to 50% persistent, with the persistence being a measure of the dry weight of the hydrogel relative to an initial dry weight of the hydrogel.

    HYDROGEL DRUG DELIVERY IMPLANTS
    3.
    发明公开
    HYDROGEL DRUG DELIVERY IMPLANTS 审中-公开
    水凝胶药物递送植入物

    公开(公告)号：EP3229779A1

    公开(公告)日：2017-10-18

    申请号：EP15820375.2

    申请日：2015-12-10

    申请人： Incept, LLC

    发明人： JARRETT, Peter ,  EL-HAYEK, Rami ,  SAWHNEY, Amarpreet S.

    IPC分类号： A61K9/00 ,  A61K47/10

    CPC分类号： A61K9/0051 ,  A61K9/50 ,  A61K39/3955 ,  A61K47/10

    摘要： Materials and methods for treating a patient, optionally a patient with an eye disease, comprising providing a collection of particles that comprise a first biodegradable material that is a hydrogel or a xerogel and a therapeutic agent, with the first material, before biodegradation, having a rate of release for the therapeutic agent as measured in physiological solution, and forming a second hydrogel
    ex vivo or
    in situ on a tissue of the patient at a site of intended use, optionally at or near an eye, that at least partially coats the collection of particles. The agent is released to treat the patient.

    摘要翻译： 用于治疗患者，任选地患有眼病的患者的材料和方法，包括提供一组颗粒，所述颗粒包含作为水凝胶或干凝胶的第一可生物降解材料和治疗剂，其中所述第一材料在生物降解之前具有 在生理溶液中测量的治疗剂的释放速率，以及在预期使用位置处，在任选地在眼睛处或附近的患者组织上离体或原位形成第二水凝胶，所述第二水凝胶至少部分地涂覆所述收集物 的颗粒。 代理商被释放以治疗病人。

    DRUG DELIVERY FROM HYDROGELS
    6.
    发明公开
    DRUG DELIVERY FROM HYDROGELS 审中-公开

    公开(公告)号：EP4279064A2

    公开(公告)日：2023-11-22

    申请号：EP23200018.2

    申请日：2016-05-12

    申请人： Incept, LLC

    发明人： JARRETT, Peter ,  EL-HAYEK, Rami ,  JARRETT, Timothy, S. ,  BLIZZARD, Charles D. ,  SAWHNEY, Amarpreet, S.

    IPC分类号： A61K9/00

    摘要： Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed in the hydrogel, the agent having a low solubility in water. The agent may be essentially insoluble in water. The hydrogel may be made so that 50% to 100% w/w of the agent is released when the hydrogel is from 100% to 50% persistent, with the persistence being a measure of the dry weight of the hydrogel relative to an initial dry weight of the hydrogel.

    INTRACAMERAL DRUG DELIVERY DEPOTS
    7.
    发明公开
    INTRACAMERAL DRUG DELIVERY DEPOTS 审中-公开

    公开(公告)号：EP4197527A1

    公开(公告)日：2023-06-21

    申请号：EP23154758.9

    申请日：2017-09-25

    申请人： Incept, LLC

    发明人： SAWHNEY, Amarpreet S. ,  DRISCOLL, Arthur ,  BLIZZARD, Charles D. ,  DESAI, Ankita Darshan ,  JARRETT, Peter

    IPC分类号： A61K9/00 ,  A61K9/16 ,  A61K47/10 ,  A61P27/06

    摘要： Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel after exposure to intraocular fluid and is degradable. The degradable particles comprise the therapeutic agent and hydrolytically degrade in the anterior chamber to provide a controlled release of the therapeutic agent into the eye. Materials and processes for making depots are provided as well as alternative methods of their use.